ELAN vs NEOG

For growth investors, Elanco Animal Health Incorporated (ELAN) is the stronger pick with 6.

2% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Elanco Animal Health Incorporated (ELAN) delivered a total return of -27.

0%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: ELAN returned -33. 3% versus NEOG's -49. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elanco Animal Health Incorporated (ELAN) is the lower-risk stock at 1.

42β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 29% more volatile than ELAN relative to the S&P 500. On balance sheet safety, Neogen Corporation (NEOG) carries a lower debt/equity ratio of 44% versus 61% for Elanco Animal Health Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Elanco Animal Health Incorporated (ELAN) is pulling ahead at 6.

2% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Elanco Animal Health Incorporated grew EPS -169. 1% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elanco Animal Health Incorporated (ELAN) is the more profitable company, earning -4.

9% net margin versus -122. 1% for Neogen Corporation — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELAN leads at 5. 3% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — NEOG leads at 47. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Elanco Animal Health Incorporated (ELAN) trades at 23.

3x forward P/E versus 25. 9x for Neogen Corporation — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEOG: 18. 9% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Elanco Animal Health Incorporated (ELAN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELAN: -33. 3%, NEOG: -49. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.